Durysta is a drug owned by Abbvie Inc. It is protected by 10 US drug patents filed in 2020. Out of these, 7 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 31, 2034. Details of Durysta's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8629185 | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof |
Jul, 2031
(6 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9980974 | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(9 years from now) | Active |
| US9492316 | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(9 years from now) | Active |
| US7799336 | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2029
(3 years from now) | Active |
| US8206737 | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2027
(1 year, 10 months from now) | Active |
| US10441543 | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(1 year, 7 months from now) | Active |
| US9149428 | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(1 year, 7 months from now) | Active |
| US8673341 | Intraocular pressure reduction with intracameral bimatoprost implants |
Feb, 2025
(2 months ago) |
Expired
|
| US10398707 | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr, 2024
(1 year, 9 days ago) |
Expired
|
| US7033605 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Durysta's patents.
Latest Legal Activities on Durysta's Patents
Given below is the list of recent legal activities going on the following patents of Durysta.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2024 | US9492316 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Nov, 2023 | US8206737 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Mar, 2023 | US10441543 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Feb, 2023 | US10398707 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Feb, 2022 | US7799336 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9980974 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Sep, 2021 | US8673341 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Jul, 2021 | US8629185 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2020 | US9492316 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Dec, 2019 | US8206737 |
FDA has granted several exclusivities to Durysta. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Durysta, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Durysta.
Exclusivity Information
Durysta holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Durysta's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2023 |
US patents provide insights into the exclusivity only within the United States, but Durysta is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Durysta's family patents as well as insights into ongoing legal events on those patents.
Durysta's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Durysta's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 31, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Durysta Generic API suppliers:
Bimatoprost is the generic name for the brand Durysta. 10 different companies have already filed for the generic of Durysta, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Durysta's generic
Alternative Brands for Durysta
Durysta which is used for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension., has several other brand drugs using the same active ingredient (Bimatoprost). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Bimatoprost, Durysta's active ingredient. Check the complete list of approved generic manufacturers for Durysta
About Durysta
Durysta is a drug owned by Abbvie Inc. It is used for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Durysta uses Bimatoprost as an active ingredient. Durysta was launched by Abbvie in 2020.
Approval Date:
Durysta was approved by FDA for market use on 04 March, 2020.
Active Ingredient:
Durysta uses Bimatoprost as the active ingredient. Check out other Drugs and Companies using Bimatoprost ingredient
Treatment:
Durysta is used for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Dosage:
Durysta is available in implant form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MCG | IMPLANT | Prescription | OPHTHALMIC |